Jazz Pharmaceuticals Q4 Revenue Up 10.1% to $1.2B, EPS of $6.64
Jazz Pharmaceuticals posted Q4 revenue of $1.2 billion, up 10.1% year over year and 1.6% above estimates, with adjusted EPS of $6.64 beating forecasts by $0.02. Neuroscience sales climbed 8.4% to $791.9 million and oncology revenues rose 15.6% to $337.3 million, while Vyxeos sales sank 34.8%.
1. Q4 Financial Highlights
Jazz Pharmaceuticals delivered $1.2 billion in revenue for the quarter ended December 2025, marking a 10.1% year-over-year increase and a 1.6% surprise over consensus. Adjusted EPS of $6.64 topped estimates by $0.02, representing a 0.27% upside.
2. Segment Revenue Breakdown
Neuroscience products generated $791.86 million (up 8.4%), led by Oxybate brands at $503.23 million (+11.8%) and Xywav alone at $465.45 million (+16.1%). Oncology revenues rose 15.6% to $337.28 million, though Vyxeos sales slumped 34.8% to $34.73 million.
3. Market Reaction and Outlook
Shares have outperformed by returning 4.2% over the past month, reflecting investor approval of the modest beats. Consensus for the coming quarter stands at $4.50 EPS on $985 million revenue, with analysts expected to monitor estimate revisions closely.